Provides regulatory counseling regarding: pre-clinical and clinical development strategies; bioequivalence and therapeutic equivalence standards; Abbreviated New Drug Application (ANDA) and 505(b)(2) New Drug Application (NDA) strategies; product classification and regulatory approval pathways; strategic use of FDA meeting opportunities; dispute resolution; labeling negotiations; and appeals of adverse FDA review decisions.
){kind=logo}
It looks like we may have content for your preferred language. Would you like to view this page in English?
Email has been submitted successfully. Thanks!
Error sending the email. Please try again later.
Error with download